contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Oriola is a pharmaceutical group with a particular focus on the distribution of pharmaceuticals to other players in the industry. The company offers services to pharmacies and other pharmaceutical companies, which includes, for example, negotiations with suppliers and distribution of products. The largest operations are in the Nordic and Baltic regions. The headquarters are located in Espoo.

Here is a company report from Rauli following Oriola’s Q4 results.  Oriola’s Q4 and this year’s guidance were in line with our expectations regarding its own operations, and we made no significant forecast changes. We are still expecting plans from the spring Capital Markets Day to clarify the group structure (especially the sale of Kronans) and to strengthen the equity ratio. We see potential for value unlocking in the company and upgrade our recommendation to Accumulate (prev. Reduce). We adjust our target price to EUR 1.2 (prev. EUR 1.25).                   Inderes              Oriola Q4'25: Arvon vapautuminen vaatii rakenteen selkiyttämistä - Inderes    Oriolan Q4 ja tämän vuoden ohjeistus vastasivat odotuksiamme omien toimintojen osalta.

Iikka interviewed Oriola’s CEO Katarina Gabrielson regarding the Q4 results                    Inderes              Oriola Q4'25: Double‑digit revenue growth - Inderes    Aika: 25.02.2026 klo 14.26 Oriola’s revenue grew 14% in Q4. Oriola’s adjusted EBITDA improved to 9.9 MEUR from 9.4 MEUR in the comparison period.                             Topics: 00:00 Introduction  00:15 Oriola’s year 2025  00:25 New distribution centre  01:13 Strategy review  01:51 Kronans Apotek profitability  03:12 Write‑off in Kronans Apotek  03:45 Dividend  04:13 Guidance

Of course the ERP isn’t ready yet, as it was stated at the beginning of 2024 that the project would last until 2027. However, it was mentioned on the call that it hasn’t been decided yet whether the old system will be used first in the new distribution center to be built in Finland in '26-27, which in my opinion doesn’t make much sense or logic given the stated schedule. Of course, both a new distribution center and a new ERP are major transitions and operational challenges, which is why doing both at once could be too challenging, considering that the last ERP update brought all Finnish operations to a standstill. I agree that the content of many of the company’s comments was indeed not very concrete.

NOT LIKE THIS! That was some tough reading, as the whole report was pure bullshit bingo. The dividend was halved, and Kronans is still a complete farce. The ERP project apparently takes forever and has failed completely; AI was also mentioned in the report, because well, I don’t know why, and apparently the company doesn’t know either.  In expert services, we have identified business opportunities in utilizing AI-based tools to improve our services, for example in the areas of commercial data and pharmaceutical information.  It’s really nice that opportunities have been identified, but do you intend to actually do something about it? That remains a mystery for now. What does this sentence even mean?  Throughout the year, we strengthened customer-centricity, which is a key strategic focus after the implementation of our new operating model.  or this one, where they’re babbling something about working  We also introduced new digital and AI-based tools that improved work and productivity.  or this sentence, which is missing any mention of profitability:  Our investments are reflected in improved NPS results, especially in customer feedback regarding product range and quality.  The ERP project is still not finished, and apparently it never will be, as it still hasn’t been brought to the finish line and the project has only “progressed”, whatever that means.  Our strategic investment in the renewal of Oriola’s enterprise resource planning (ERP) and warehouse management system (WMS) progressed during the year.  In my opinion, it makes no sense for the company to organize a Capital Markets Day if the CEO isn’t fired before then.

The bot interpreted this somewhat confusing reporting quite well, but here’s my quick comment as well                   Inderes              Oriola Q4’25 -pikakommentti: Omat toiminnot karkeasti odotuksiin, Kronansista...    Oriolan omien toimintojen tulos osui suunnilleen odotuksiimme ja ohjeistus tulosparannuksesta tälle vuodelle oli odotettu.

Inderes              Oriola Oyj:n tilinpäätöstiedote 1.1.- 31.12.2025 - Inderes    Oriola Oyj:n pörssitiedote 25.2.2026 klo 8.30Oriola Oyj:n tilinpäätöstiedote 1.1.- 31.12.2025Oikaistun käyttökatteen ja strategisten tavoitteiden vakaa kehitysLoka-joulukuun 2025 pääkohdat Laskutus...                             October–December 2025 highlights  Invoicing increased by 12.8 percent to EUR 1,109.8 (983.5) million. Net sales increased by 13.9 percent to EUR 502.0 (440.7) million. Gross margin increased by 2.0 percent to EUR 43.3 (42.4) million. Adjusted EBITDA was EUR 9.9 (9.4) million. EBITDA was EUR 5.8 (7.0) million, including EUR -4.1 (-2.4) million in adjusting items. The result for October–December was EUR -18.0 (-17.8) million and earnings per share were EUR -0.10 (-0.10). The loss includes Oriola’s share of the result of the joint venture Kronans Apotek, EUR -18.9 (-19.5) million, which includes Oriola’s share of goodwill impairment of EUR 15.8 (16.3) million. Free cash flow was EUR 46.8 (39.2) million.  EDIT: Flash comment:                  Inderes              Robokommentti Oriolan Q4-tuloksesta - Inderes    Oriolan Q4-liikevaihto ylitti odotuksemme selvästi vahvan kasvun jatkuessa molemmissa segmenteissä, mutta kasvu valui heikosti tulokseen myyntikatteen jäädessä vaatimattomaksi suhteessa liikevaihtoon. Oik. käyttökate oli linjassa odotuksiimme, mutta...

Here are Rauli’s pre-comments as Oriola reports its Q4 results on Wednesday  Oriola will publish its Q4 interim report on Wednesday, February 25, 2026, and the company’s results presentation can be followed here at 10:00. We expect Oriola’s revenue to have continued its growth and the adjusted EBITDA to have improved from the comparison period. However, the reported result will be weighed down by the significant write-down in the value of the Kronans Apotek joint venture announced in December. In addition to the results and outlook, our interest is focused on the company’s balance sheet position and the dividend proposal.                   Inderes              Oriola Q4'25 -ennakko: Reseptissä tuloskasvua, mutta osinko joutuu kuurille -...    Ennustamme osingon laskevan 0,04 euroon taseen vahvistamiseksi – heikko tase voi vaatia jopa osakeantia.

Oriola

Oriola posted overall good figures in Q4. Net sales and invoicing growth was in the double-digits, and the pace exceeded our expectations. The adj. EBITDA of EUR 9.9m fell slightly short of ...

Oriola posted overall good figures in Q4. Net sales and invoicing growth was in the double-digits, and the pace exceeded our expectations. The adj. EBITDA of EUR 9.9m fell slightly short of our EUR 10.3m expectations, as the profitability in the Wholesale-segment remained subdued. Oriola expects the adj. EBITDA to increase in 2026 compared with 2025.